Compare Heron Therapeutics Inc (HRTX) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ON Holding AG — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while ON Holding AG trades at $34 (market cap $11.38B). The key difference: ON Holding AG is far larger — about 167.3× Heron Therapeutics Inc's market cap, and ON Holding AG is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and ON Holding AG for 22 Days on average.
| HRTX | ONON | |
|---|---|---|
Market Cap | $68.01M | $11.38B |
Volume | 1,891,941 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $50.63 |
52-Week Low | $0.27 | $26.76 |
Typical Hold Time | 35 Days | 22 Days |
Enterprise Value | $174.75M | $10.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
ONON trades at $33.22, up 0.27% with a bullish technical outlook supported by moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.44 exceeding the $0.42 consensus. Strong fundamentals include 64.8% gross margins and 23.95% ROE, while analyst sentiment remains positive with 74% buy ratings and a $42.26 price target representing 27% upside potential.
The stock offers growth potential through premium store expansion and new sports category launches, supported by a $1 billion buyback program through 2029. Key risks include high valuation multiples (P/E 24.02, P/S 5.67) and potential execution challenges in achieving ambitious 2029 targets of CHF 5.6 billion in sales. Recent investor day enthusiasm must be balanced against competitive pressures in the athletic footwear market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
